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Abstract
Background: Glioblastoma multiforme (GBM) is the most common and aggressive type of brain tumor in humans and the
first cancer with comprehensive genomic profiles mapped by The Cancer Genome Atlas (TCGA) project. A central challenge
in large-scale genome projects, such as the TCGA GBM project, is the ability to distinguish cancer-causing ‘‘driver’’ mutations
from passively selected ‘‘passenger’’ mutations.
Principal Findings: In contrast to a purely frequency based approach to identifying driver mutations in cancer, we
propose an automated network-based approach for identifying candidate oncogenic processes and driver genes. The
approach is based on the hypothesis that cellular networks contain functional modules, and that tumors target
specific modules critical to their growth. Key elements in the approach include combined analysis of sequence
mutations and DNA copy number alterations; use of a unified molecular interaction network consisting of both
protein-protein interactions and signaling pathways; and identification and statistical assessment of network
modules, i.e. cohesive groups of genes of interest with a higher density of interactions within groups than between
groups.
Conclusions: We confirm and extend the observation that GBM alterations tend to occur within specific functional modules,
in spite of considerable patient-to-patient variation, and that two of the largest modules involve signaling via p53, Rb, PI3K
and receptor protein kinases. We also identify new candidate drivers in GBM, including AGAP2/CENTG1, a putative
oncogene and an activator of the PI3K pathway; and, three additional significantly altered modules, including one involved
in microtubule organization. To facilitate the application of our network-based approach to additional cancer types, we
make the method freely available as part of a software tool called NetBox.
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Introduction
Glioblastoma multiforme (GBM) is the most common and
aggressive brain tumor in humans [1–3], and the first cancer type
to undergo comprehensive genomic characterization by The
Cancer Genome Atlas (TCGA) project [4]. Glioblastoma is
classified into two broad categories: primary and secondary.
Primary glioblastomas (accounting for w90% of cases and most of
the TCGA cases profiled) manifest de novo without prior evidence
of preexisting tumor; secondary glioblastomas develop through
malignant progression from lower grade astrocytomas [3].
Prognosis for glioblastoma patients remains dismal, as most
patients die within one year after diagnosis [3] and generally
respond poorly to current therapeutic approaches [4,5].
High-throughput cancer genomic studies, such as those being
organized by the TCGA and the International Cancer Genome
Consortium (ICGC) [6], are now enabling the research commu-
nity to examine the cancer genome in a comprehensive and
unbiased manner [7]. These efforts will soon lead to a
comprehensive catalog of altered genes, altered biological
processes and, by implication, therapeutic vulnerabilities in
cancer. For example, the TCGA GBM project has cataloged
somatic mutations and recurrent copy number alterations in
GBM, and has identified frequent alterations in the p53, RB, PI3-
kinase (PI3K) and receptor tyrosine kinase (RTK) signaling
pathways [4].
A fundamental and open challenge in cancer genomics is the
ability to distinguish ‘‘driver’’ from incidental ‘‘passenger’’
mutations. To first approximation, driver mutations are those
that confer the tumor with some selective advantage in growth and
contribute to tumorigenesis, whereas passenger mutations do not
[8]. A number of approaches have been developed to distinguish
drivers from passengers, including those that examine the rate of
synonymous versus non-synonymous mutations [8], those that
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approaches that assess the overall rate of recurrence, based on
combined rates of sequence mutation and copy number alteration
[10]. A more recent approach by Torkamani et. al. [11] sought to
identify cancer drivers by identifying an enrichment of rare cancer
mutations within network modules reconstructed from gene
expression studies. Here, we also present a network-based
approach to identifying driver mutations in cancer, apply this
approach to GBM, and discuss potential applicability to other
cancer types.
Our network-based approach is based on the hypothesis that
cellular networks are modular, and consist of inter-connected
proteins responsible for specific cellular functions [12,13]. It is
further based on the hypothesis that the cancer phenotype is based
on the inability of multiple genetic functional modules to carry out
their basic functions, and that functional modules are critical to the
‘‘hallmarks of cancer’’, including self-sufficiency in growth signals,
evasion of apoptosis, sustained angiogenesis, tissue invasion and
metastasis [14]. Furthermore, different combinations of perturbed
genes can incapacitate each module [15], and each tumor can
perturb individual genes via multiple mechanisms including
sequence mutations, copy number alterations, gene fusion events,
or epigenetic changes. Evidence for such universality at the
module-level, but diversity at the genetic level can be seen in
multiple cancer types, including in glioblastoma. For example,
nearly all GBM tumors contain alterations in the p53 tumor
suppressor pathway, but individual tumors exhibit diverse
mechanisms for pathway alteration – mutation or homozygous
deletion of TP53, mutation or homozygous deletion of CDKN2A/
ARF, or amplification of MDM2/MDM4. If tumors frequently
target biological modules that execute key biological processes,
and network knowledge about such modules is available, we
hypothesized that it would be possible to algorithmically identify
frequently perturbed modules, and from these modules identify
candidate driver mutations.
Results and Discussion
A Network-Based Approach for Distinguishing Driver
from Passenger Mutations
We performed integrated network analysis to identify frequently
altered network modules and candidate driver mutations in
glioblastoma. The network analysis is summarized in Figure 1.
We began by constructing a global Human Interaction Network
(HIN). Due to the potentially high rate of false positives and false
negatives associated with high-throughput protein-protein inter-
action detection techniques [16] and natural language processing
(NLP) algorithms [17], we chose to construct the HIN of literature
curated data sources only (see Methods). To cover increased
network territory, we also chose to create a unified HIN consisting
of both protein-protein interactions and signaling pathways. The
final network consists of genes, represented as nodes, and
interactions, represented as edges. Interactions represent any
functional association between two genes, such as a direct protein-
protein interaction, membership in the same complex, or a state
change event, such as a phosphorylation event. Redundant edges
in this network may exist if multiple data sources have evidence for
the same interaction. Since the module detection algorithm
described below does not take into account multiple lines of
evidence or self-directed edges, all redundant edges were collapsed
into single edges, and all self-directed edges were pruned from the
network.
To gain a global view of genomic alterations occurring in
glioblastoma, we restricted our analysis to the 91 TCGA GBM
cases, for which both copy number and sequence mutation data
were available. Seven of these cases were treated with adjuvant
chemotherapy and classified as hypermutators, and were excluded
from the analysis. To focus on minimally recurrent alterations, we
also only included genes that were altered in two or more of the
final 84 cases. As was the case in the original TCGA pathway
analysis, only unequivocal genetic alterations were included [4].
This includes validated non-synonymous somatic nucleotide
substitutions, and likely homozygous deletions and multi-copy
amplifications, as determined by the RAE algorithm (see
Methods).
A total of 517 genes passed the frequency threshold. Of these,
274 genes had interactions in the human interaction network
(HIN). We next tried to connect these 274 genes into a network,
based on prior known interactions in the HIN. Our goal was to
include interactions between altered genes, and to simultaneously
identify biologically informative ‘‘linker’’ genes which were not in
the original altered list, but which were statistically enriched for
connections to member of the GBM gene list. By including such
linkers, we aimed to connect more genes in the original gene list,
and to provide greater biological context for module discovery and
interpretation. For each pair of genes, we found all shortest paths
of lengths 1 and 2 connecting the two genes in the HIN. If two
genes are connected via a shortest path of 1, they are directly
connected via an interaction. If two genes are connected via a
shortest path of 2, there may be multiple paths of length two, each
of which includes a unique linker gene. To retain information rich
linker genes only, we applied a statistical threshold test for local
enrichment. The statistical threshold uses the global degree of each
linker gene within the HIN and the hypergeometric distribution to
assess the probability that the linker gene would connect to the
observed number of altered genes by chance alone. After FDR
correction, linker genes which do not pass a p-value threshold of
0.05 were pruned from the network. Using a shortest path
threshold of 2 and a FDR-adjusted p-value cut-off of: 0.05, we
were able to connect 66 GBM altered genes and identify 6 linker
genes.
To assess the level of global connectivity in the observed GBM
network, we compared the size (number of nodes and edges) of the
largest component in the network to the largest component
generated by randomly selected sets of genes known to be present
in the HIN. At each of 1000 iterations, we randomly selected 274
genes from the HIN and connected them via the same shortest
path threshold and p-value cut-off parameters. This test showed
that the GBM network is highly connected, more so than expected
by chance (number of nodes =55, p-value: 0.014; number of
edges =135, p-value: 0.01).
Finally, we partitioned the GBM network into network modules
or communities — clusters of network nodes joined together in
tightly knit groups, between which there are only looser
connections [18]. This community structure or network modular-
ity has been identified in diverse network systems, including social
[18,19], scientific collaboration [20], metabolic [21], and molec-
ular interaction networks [22–24]. Numerous network module
algorithms have been proposed, including those that take into
account network topology alone, and those that take into account
network topology plus additional biological information, such as
correlated gene expression or subcellular localization [23,25–27].
We chose to use the widely used edge betweenness algorithm by
Girvan and Newman [18] for modularity detection. In this final
step, we also calculated the modularity of the partitioned GBM
network. This is a well-defined measure in network analysis that
quantifies the extent of modularity seen in an observed network
(see Methods).
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detected a total of 10 modules, with an overall network modularity
of 0.519. Random graphs and scale-free graphs can exhibit a
relatively high degree of modularity [28]. We therefore chose to
assess the statistical significance of the observed network
modularity in relation to a null model of random networks of
the same size and same degree distribution. To do so, we
performed 1000 random simulations — in each simulation, the
observed GBM network was locally rewired, such that all genes
had exactly the same number of connections as before, but the
choice of interaction partners was random [29]. For each random
network, the network modularity score was recalculated, and the
observed modularity score was then converted to a z-score or a
scaled modularity score [30]. One thousand local rewiring
simulations found an average network modularity of 0.296, with
a standard deviation of 0.058. This resulted in a scaled modularity
score of: 3.84, providing evidence that the GBM network is more
modular than random.
Properties of the GBM Network
The main set of network modules identified in glioblastoma is
shown in Figure 2. From these modules, we can make two initial
observations. First, the network-based approach identifies many of
the same driver candidates as the original TCGA frequency-
based approach used to assess mutational significance. The
original TCGA approach (with false discovery rate v10{3)
initially identified eight genes as significantly mutated. Notably,
seven of these genes appear within the GBM network, and all
seven appear within the two largest modules (NF1 does not appear
within the network). Additional, while no strict statistical cut-off
was used to assess genes individually altered by copy number
alteration in the original analysis, many of the genes that are
Figure 1. Overview of the network approach for identifying oncogenic processes and candidate driver genes in GBM. We began by
creating a literature curated Human Interaction Network (HIN) derived from protein-protein interactions and signaling pathways (A), and assembling
genomic alterations in GBM (B). We then extracted a GBM-specific network of altered genes (C), which was then partitioned into network modules
(D). We assessed the level of connectivity seen within the GBM network by using (E1) a global null model to compare the size of the largest
component in the observed network v. networks arising from randomly selected gene sets; and (E2) a local null model to compare network
modularity of the observed network to locally rewired networks.
doi:10.1371/journal.pone.0008918.g001
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including EGFR, CDK4, CDKN2A/B, PTEN, MDM2 and MDM4
are all also identified within the GBM network.
Second, the two largest modules identified by network analysis
correspond very closely to the three critical signaling pathways
identified in the original TCGA pathway analysis. These modules
also correspond well to genetic and pathway alterations known to
GBM biology prior to TCGA analysis [2]. For example, the p53
tumor suppressor pathway, which prevents the propagation of
unstable genomes, is frequently altered in glioblastoma [2].
Alterations within the p53 pathway include mutations and
deletions of TP53, homozygous deletion of CDKN2A,a n d
amplifications of MDM2 and MDM4 [2,4]. The algorithmically
identified RB1 module contains all of these known genetic
alterations (Figure 3A). Glioblastomas also nearly universally
circumvent cell cycle inhibition through genetic alterations to the
RB pathway [2]. These alterations include mutations in RB1
[31,32], amplifications of CDK4 [33], CDK6 [34] CCND1 or
CCND2; and homozygous deletions of CDKN2A, CDKN2B,o r
CDKN2C [4]. All of these alterations, with the exception of CCND1,
which did not meet our frequency threshold, are also clustered
together within the RB1 module identified by network analysis
(Figure 3A). Notably, CDK6 was not included in the original input
list, but was identified as a statistically significant linker gene.
Figure 2. Network modules identified in GBM. (A) Modules are densely connected sets of altered genes that may reflect oncogenic processes. A
total of 10 modules were identified, the largest of which are shown. Linker genes, indicated in red, are not altered in GBM, but are statistically
enriched for connections to GBM-altered genes. (B) The observed modularity of the GBM network (0.519) is compared with 1000 randomly rewired
networks (average 0.296, standard deviation 0.058). This results in a z-score, or scaled modularity score, of 3.84.
doi:10.1371/journal.pone.0008918.g002
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is the PIK3R1 module. This module contains many members of
the phosphatidylinositol 3-Kinase-AKT pathway, also a frequent
target of disruption in glioblastoma [2]. Major downstream effects
of PI3K/AKT activation include cell growth, proliferation,
survival and motility, all factors that drive tumor progression.
Known alterations in the pathway include frequent alterations to
receptor tyrosine kinases, homozygous deletion of PTEN, homo-
zygous deletion of NF1, mutations in AKT, and alteration to
components of the PI3K complex [2,4]. The PIK3R1 module
includes all of these alterations, with the exception of NF1 and
AKT. Identified members include PTEN, receptor tyrosine kinases:
EGFR, PDGFRA, and ERBB2. It also includes two subunits of the
Class I PI3K complex, including the p110 catalytic subunit
PIK3CA, and the p85 regulatory subunit PIK3R1 (Figure 3B).
To test the robustness of these initial observations, we
performed network analysis of mutated genes discovered in a
separate unbiased re-sequencing effort in GBM [35]. For this, we
used the set of 40 GBM candidate cancer genes (CAN-genes) that
are most likely to be cancer drivers. Using a shortest path
threshold of two and a linker p-value cut off of 0.001, we were able
to place 10 CAN genes into a network context and identify 9
significantly enriched linker genes. Network partitioning was then
able to identify two main modules, one corresponding to the
components of the PI3K pathway (including EGFR, PTEN,
PIK3CA, and PIK3R1), and one corresponding to the components
Figure 3. Automated network analysis approach is in close agreement with previous manually curated pathway analysis
approach. The original pathway analysis of TCGA glioblastoma datasets was derived by mapping observed gene alterations onto a manually
curated GBM-specific network, based on the glioblastoma literature. This non-algorithmic analysis identified driver alterations in the p53, RB and
PI3K pathways. Our automated network analysis approach is in close agreement with these results (top: P53/Rb; bottom: PI3K). The one main
exception is that network analysis does not identify NF1 as a participant in the PI3K module. Additional candidate driver genes identified by
network analysis, including AGAP2, are identified and annotated on the right. Percentage values after each newly identified candidate driver
indicate percent of cases with genetic alterations (sequence mutations, homozygous deletions, or multi-copy amplifications) across the 84 TCGA
GBM cases analyzed.
doi:10.1371/journal.pone.0008918.g003
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RB1) (data not shown). Despite the much smaller sample size used
in the Parsons study, network analysis was also able to identify 6 of
the 8 genes identified as significantly mutated in the TCGA study,
and the main two-module signature is also present in the Parsons
data set. From this, we can conclude that the the module signature
is robust across both data sets and the modules are frequently
altered across patients profiled in both studies.
In summary, a network-based approach identifies many of the
same candidates as the original frequency-based approach used to
assess mutational significance. Furthermore, GBM alterations
cluster within non-random modules, and the modules are robust
across different studies; and a network-based approach can
automatically identify and extract biologically relevant GBM
modules, which correspond closely to prior known GBM biology.
Identification of AGAP2 and Additional Candidate Drivers
in the PIK3R1 Module
As has been noted by others, clustering of networks into modules
can be used to direct experimental research by providing a
functional context for previously uncharacterized genes [23]. In our
case, network module analysis identifies new candidate driver genes
within previously identified p53/RB and PI3K signaling modules,
and within newly identified modules in glioblastoma. For example,
within the PIK3R1 module, the most notable new driver candidate
is AGAP2, a gene which has been previously implicated in human
glioblastoma [36], but was not reported in the first TCGA pathway
analysis [4]. AGAP2,a l s ok n o w na sPIKE and CENTG1, is amplified
in 19% of the GBM cases, and is is frequently co-amplified with
Cyclin-dependent kinase 4 (CDK4) in a variety of human cancers,
including sarcoma, glioblastoma, and neuroblastoma [37]. As
CDK4 is known to phosphorylate Rb, and is a known oncogene,
the independent oncogenic role of AGAP2 is in question. However,
recent evidence indicates that PIKE-A, one of the three isoforms of
AGAP2, specifically binds to active AKT [37], and that PIKE-A is a
proto-oncogene capable of promoting cell proliferation and
invasion [38]. AGAP2 may therefore indeed be a driver in GBM
oncogenesis, and may represent an alternative or additional means
by which glioblastoma tumor cells activate the PI3K pathway, and
its downstream effects, including cell proliferation, inhibition of
apoptosis, and tumor invasiveness. However, as with all such
predictions regarding driver genes, definitive evidence can only be
provided by further functional studies.
Other new candidate driver genes altered in at least 5% of
GBM cases, but not detected by a previous frequency-based
mutation significance test or previous pathway analysis include:
AVIL, KIT, TEK, FRS2, and KDR. AVIL is implicated primarily by
multi-copy amplifications (18% of cases), is in the shoulder of the
CDK4/AGAP2 amplicon, and may play a role in the development
of neuronal cells that form ganglia [39]. KIT and KDR are both
located in the shoulder of the PDGFRA amplicon, which may
represent the true target of amplification. However, these genes
may represent additional drivers and targets of amplification. For
example, KIT has been identified as a proto-oncogene, and has
been previously implicated in glioblastoma [40–42]. KDR encodes
one of the two receptors of the Vascular Endothelial Growth
Factor (VEGF), and maintains a key role in regulating angiogen-
esis-related functions [43]. Notably, the TEK receptor tyrosine
kinase (located in the shoulder of the CDKN2A deletion), is also
involved in angiogenesis, and is the receptor for angiopoietin-1
[44]. As is the case with AGAP2, and all other predictions
regarding driver genes, definitive evidence regarding the role of
these genes in GBM oncogenesis can only be provided by further
functional studies.
Identification of Additional Modules and Candidate
Drivers
In addition to the two main modules, network analysis also
identified eight additional modules. Three of these modules
contained four or more genes, and are briefly summarized below
and in Figure 4.
The DCTN2 module is altered in 17% of all GBM cases, and
includes four genes: DCTN2, TUBGCP2, TUBGCP6, and
FGFR1OP. All four of the genes are located in the centrosome
and microtubule organizing center (FDR adjusted p-value:
0:0012). Centrosomes are critical to organizing the interphase
cytoskeleton and the bipolar mitotic spindle, both of which are
critical to ensuring the correct segregation of chromosomes during
cell division. Centrosomes also serve as a ‘‘command center’’ for
integrating multiple cell cycle and repair signals, including
CHEK1, CHEK2, ATM, BRCA1, and ATR in response to
DNA damage [45]. We hypothesize that alteration of centrosome-
related genes cause dysregulation of chromosomal segregation
and/or normal DNA damage response, either of which could lead
to increased genomic instability in GBM.
The NUP107 module is altered in 19% of all GBM cases, and
includes four genes: SNRPE, THOC4, NUP107, NUP50. The
module is not enriched for any GO processes, but two of the genes,
NUP50 and NUP107 are components of the nuclear pore complex.
The IFNAR1 module is altered in 25% of all GBM cases, and
includes four altered genes: IFNA1, IFNA2, IFNB1, and IFNW1
and one linker gene: IFNAR1. Notably, all four of the genes are
involved in interferon-alpha/beta receptor binding (FDR adjusted
p-value: 1:0|10{7), but all genes are also located on chromosome
9p, proximal to CDKN2A, which is a clear target of focal deletion.
The genes could therefore be passenger deletions and deleted as a
consequence of their proximity to CDKN2A.
Availability of Software
To facilitate the application of our network-based approach to
additional cancer types, we have made our software freely
available as part of a command line tool, called NetBox. NetBox
is pre-loaded with the Human Interaction Network (HIN) defined
above, and provides a simple command line interface for
connecting genes into a network, identifying linker genes,
partitioning the network into modules, and executing the random
background models. Results are then made available to the end
user as an HTML web page and a series of network and attribute
files, which can be loaded into Cytoscape [46] for visualization and
further analysis. The NetBox software, user guide, and GBM data
sets are available for download at: http://cbio.mskcc.org/netbox.
Conclusions
One of the central challenges confronting high-throughput
cancer genomics is the ability to sift through the deluge of
genomic profiling data and discern the true cancer signals from a
general background of overall genomic instability. One of the
most successful approaches to discerning the signal in mutation
data or in copy number alteration data is to seek out those genes
or regions which are altered at a frequency above a background
random model. However, such an approach may only identify
the most prominently altered genes, many of which may have
already been known prior to the large investment in resequen-
cing. And, while the focus on frequent regions of copy number
alteration identifies many narrowly defined regions with few
target genes, many regions contain dozens, if not hundreds of
potential targets, and it is difficult to determine which of these
represent the true targets.
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cancer signals and candidate drivers, we and others [11] have
proposed a network-based approach to the problem. Our
approach is based on the hypothesis that tumors target specific
biological modules of critical importance, and that such modules
can be algorithmically identified based on network topology alone.
Such an approach does, however, have certain drawbacks. First,
network analysis is only as good as the network itself. Human
interaction and pathway data remain sparse and fragmented, and
we must assume that the Human Interaction Network (HIN) used
here represents a small portion of the full human interactome [47].
Furthermore, interactions and pathways in our network are
completely devoid of the context in which they were originally
described, and we can only use the HIN as an approximate model
for in vivo interactions. As a quality filter, we have also specifically
chosen to include literature-curated interactions and pathways, but
this may bias the network towards disease-associated genes.
Second, distinguishing genes implicated by copy number alter-
ations remains problematic, even when candidate genes are
filtered through a network. For example, KIT, KDR and PDGFRA
are all located at 4q12, a region of frequent amplification in GBM,
and it is difficult to determine which one(s) are the true targets.
Despite these challenges, our network-based approach is able to
automatically identify the main p53, Rb and PI3-kinase signaling
modules, providing support for our hypothesis and our approach. It
also identifies new candidate drivers, including AGAP2/CENTG1,a
putative oncogene and an activator of the PI3K pathway, and three
new modules of potential interest. Unlike the network-based
approach proposed by Torkamani [11], our approach is based
specifically on integrating mutation and copy number data, uses a
Figure 4. Network analysis identifies three additional altered modules, including the DCTN2 module, which is involved in
microtubule organization. Each of the altered modules is implicated by homozygous deletions or multi-copy amplifications across the 84
analyzed GBM cases. Each module is annotated with Gene Ontology enrichment, chromosome location, statistical significance of copy number
alteration against a background model of random aberrations, as determined by RAE copy number analysis; assessment of correlation between copy
number and mRNA expression, and genomic signature across 84 GBM cases.
doi:10.1371/journal.pone.0008918.g004
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inferred from gene expression studies), and is not focused
exclusively on rare mutations alone. We have also made our
approach freely available within the NetBox software tool.
Future Directions
We anticipate several possible future directions for our work. (1)
More alteration data: the next phase of the TCGA GBM project
will be sequencing over 6,000 gene and microRNA targets in
several hundred additional GBM cases, as well as a number of
tumor and paired normal complete genome sequences. This will
provide much higher resolution, and a much broader coverage of
genes, both of which will enable us to more effectively perform
higher confidence network analysis and identify new candidate
drivers and modules. (2) Larger network: we aim to broaden our
network coverage by integrating the currently used literature
curated networks with those derived from high-throughput
protein-protein detection methods and microRNA prediction
target programs, with appropriate quality filters. (3) Epigenetic
data: we aim to integrate methylation, histone modification and
unexpected expression changes into our analysis. (4) Quality of
mutations: we plan to weight non-synonymous mutations with the
likely functional impact based on analysis of residue conservation
patterns and protein 3D structures. (5) Correlated events:
correlation and anticorrelation between alteration events within
and between modules can provide clues as to oncogenic history
and as to likely vulnerabilities to targeted intervention. (6) Tumor
subtypes: module alteration patterns, and possibly module
structure is likely to differ between different tumor subtypes, such
as the EGFR, PDFGRA and NF1 subtypes of GBM. (7) Diverse
cancers: it will be of particular interest to investigate the common
module features and characteristic differences for different cancer
types, starting with the next two TCGA target cancers, ovarian
and lung cancer. The extensions may provide additional insights
into the nature of altered molecular processes in cancer.
Methods
GBM Mutation Data and Copy Number Analysis
Sequence mutation and DNA copy number alteration data for all
TCGA GBM cases was obtained from the TCGA data portal [48].
Mutation data is only available for the 601 genes selected for
resequencing in Phase 1 of the GBM project, and only for 91 GBM
cases. For copy number data, 216 glioblastoma tumors were
analyzed with RAE, as previously described [4,49]. For all isoforms
of autosomal genes in RefSeq (hg18), we discretized copy number
using the multi-component model in RAE. We assign one of five
putative aberration states to each isoform and tumor from
overlapping regions of the unified breakpoint profile: (i) homozygous
deletion (D1§0.9), (ii) heterozygous loss (D0§0.9 and D1v0.9), (iii)
copy-neutral (D0 and A0v0.9), (iv) single-copy gain (A0§0.9 and
A1v0.5), and (v) multi-copy amplification (A0§0.9 and A1§0.5).
In the event of discontinuous coverage of a coding locus by regions
that harbor intragenic breakpoints in copy-number segmentation,
the region of extreme value in Ax and Dx respectively determines
the assigned state. Statistical significance of genomic alteration was
assigned to genes as the minimum q-value from the one to many
genomic regions that span each coding locus as determined by RAE.
These include significance levels determined either by a model of
total genomic gain/loss or a model designed to detect uncommon
amplification and homozygous deletion events with little evidence of
low-level changes (for details refer to [4,49]).
An alteration frequency score for each gene was calculated,
based on the 84 GBM cases with both sequence mutation and
copy number data (hypermutators excluded). Each gene was
considered altered if modified by a validated non-synonymous
somatic nucleotide substitution, a homozygous deletion or a multi-
copy amplification; all other copy number events were ignored, as
was originally done in the original TCGA pathway analysis [4].
Network results were compared to the manually curated GBM
network, as obtained from Figure S8 of the TCGA manuscript [4].
Individual gene and gene set alteration frequencies were obtained
from the cBio Cancer Genomics Data Portal [50].
Creation of the Human Interaction Network (HIN)
Interaction data from HPRD (Release 8: July 6, 2009) was
obtained from the HPRD web site (http://www.hprd.org/) on
Monday, September 28, 2009. Pathway data sets for Reactome
(Release 29: June 24, 2009), NCI/Nature Pathway Interaction
Database (November 12, 2008 Release), and the MSKCC Cancer
Cell Map (May 19, 2006 Release) were downloaded in BioPAX
format from Pathway Commons (http://www.pathwaycommons.
org) on Monday, September 28, 2009.
Pathways in BioPAX are represented as sets of biochemical
processes with inputs, outputs, and catalysts. A protein is often
represented in multiple post-translational states, complexes, or
cellular locations. However, most module discovery algorithms
were developed for binary association networks where each
biological entity is represented by a single node. To address this
mismatch, we developed a set of rules for mapping subgraphs of
biochemical networks to binary interactions. For example a
phosphorylation reaction in BioPAX would be recognized as a
‘‘state change’’ interaction by the simple interaction rules
(Figure 5). Similar reductions have been described by different
groups in the past [51,52] but these were limited to a single rule
per study. Our current set of rules covers molecules participating
in the same reaction or complex, and molecules catalyzing
consecutive reactions, or co-controlling the same set of processes.
The full list of rules and their explanations can be found at the
Pathway Commons web site [53]. Rules were implemented in Java
within a flexible and expandable framework and are available as a
part of the open-source Paxtools library [54]. We have also made
binary networks for each of the data sources in Pathway Commons
available for download at: http://www.pathwaycommons.org.
Figure 5. BioPAX to binary interaction mapping: example
mapping rule. To integrate complex signaling pathway data into our
Human Interaction Network (HIN), we have developed a set of rules for
mapping subgraphs of biochemical networks to binary interactions. An
example rule for mapping state changes, such as phosphorylation
events, is shown.
doi:10.1371/journal.pone.0008918.g005
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self-directed edges were pruned from the network. After edge
pruning, the final network consists of 9,264 genes and 68,111
interactions.
Identification of the GBM network and statistically
significant linker genes. To determine the network of GBM
altered genes, we began by creating an empty graph G. For each
GBM altered gene X, we queried the HIN for all neighbors of X
and placed these genes and interactions in G. Neighbor nodes of
degree 1 are connected to exactly one altered gene, but do not
inter-connect any altered genes, and are therefore immediately
pruned from the network. Remaining neighbor nodes of degree
$2 represent candidate linker genes, which connect two or more
altered genes within the network. To identify statistically
significant linker genes, we used the global degree of each linker
gene within the HIN and the hypergeometric distribution to assess
the probability that the linker gene would connect to the observed
number of altered genes by chance alone. After FDR correction
via Benjamini Hochberg [55], linker genes above a p-value
threshold of 0.05 were pruned from the network. Finally, we
queried the HIN for interactions between remaining linker genes,
and added these to G.
Module Detection
Modularity score. Modularity measures the fraction of edges
in a network that connect nodes within-modules minus the
expected value of the same quantity of edges in a network with the
same module divisions but random connections between nodes
[19]. It is measured by:
M~
X NM
s~1
ls
L
{
ds
2L
   2 "#
ð1Þ
where NM is the number of modules, ls is the number of edges
within module s, L is the total number of edges in the network,
and ds is the sum of the degrees of all nodes within module s
[19,56]. If the number of within module edges is no better than
random, the modularity value will approach 0; values approaching
1 indicate strong modular structure [19].
Module detection. We used the edge betweenness algorithm
originally proposed by Girvan and Newman [18] to detect network
modules, and implemented by the EdgeBetweennessClusterer in
the Java JUNG library [57]. The JUNG implementation is a slight
modification of the original algorithm and requires that one pre-
specify the number of edges to be removed. As recommended in
[19], we extended the JUNG implementation to sequentially
remove all edges, and recalculate the network modularity after
each edge removal, and automatically identify the number of edges
which results in the optimal / maximum network modularity.
Global random gene set null model. To assess the level of
global connectivity seen in the GBM network, we compared the
size (number of nodes and edges) of the largest component in the
network to the largest component generated by randomly selected
sets of genes known to be present in the HIN. At each of 1000
iterations, we randomly selected 274 genes from the HIN and
connected them via the original shortest path threshold and p-
value cut-off parameters. We then determined the size of the
largest component within this randomly generated network, and
determined an empirical p-value by keeping track of the number
of times this largest component equaled or exceeded the observed
largest component.
Local random rewiring null model. To assess the statistical
significance of the network modularity observed in the GBM
network, we used a local rewiring algorithm, such that random
networks maintain the same size and all genes maintain the same
degree, but the choice of interaction partners is random [29]. For
each random network, we calculate the network modularity, and
calculate the average and standard deviation for the entire set of
random networks. The observed modularity score is then converted
into a z-score, or scaled modularity score to measure the deviation
of the observed network from its random null model [30].
Network Visualization and Module Analysis
Networks were visualized in Cytoscape [46]. Modules were
visualized as discrete colors and gene alteration frequencies were
visually resized in proportion to alteration frequency across the 84
analyzed GBM cases. Gene Ontology (GO) enrichment analysis
was performed using DAVID [58,59], using a background
population of all genes in the Human Interaction Network
(HIN). Correlation between discretized copy number calls and
gene expression was assessed via ANOVA in R version 2.7.2.
NetBox Software
The NetBox software, available at http://cbio.mskcc.org/
netbox, is written in the Java and Python programming languages.
It uses the Java HyperSQL embedded database to store the
Human Interaction Network (HIN) and Entrez Gene information,
and the Java JUNG library for all graph operations. To run the
software, users must have Java 1.5 (or later) and Python 2.5 (or
later) installed.
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